# NAD+: Research Overview — Research Peptides US > NAD+: research overview covering mechanism, NMN and NR human dosing trials, the 2025 clinical-evidence review, and cited cautions on IV NAD+ contamination risk. No dosing, no sales, no advice. The cell's core energy coenzyme, sold as a supplement and an IV drip — with solid human data showing it raises blood NAD+, and much weaker data on whether that translates into anything else. ## The short version NAD+ (nicotinamide adenine dinucleotide) is not a synthetic research peptide like the others on this desk — it's a coenzyme every cell in the body already makes and uses to convert food into energy. It also acts as fuel for a set of enzymes (sirtuins, PARPs, CD38) tied to DNA repair and aging biology. Levels of NAD+ measurably decline with age, which is the entire rationale behind the current wave of NAD+ boosting supplements and IV therapy. The straight-talk version: human trials clearly show that taking NAD+ precursors — compounds called NMN and NR that the body converts into NAD+ — reliably raises blood NAD+ levels, in a dose-dependent, well-tolerated way. What's far less settled is whether raising blood NAD+ actually produces the anti-aging or performance benefits it's marketed for. A 2025 review of the human evidence is blunt about this gap: efficacy data are still limited, and the field needs more human studies rather than continuing to lean on rodent extrapolation. ## What it is NAD+ is a dinucleotide — two linked nucleotide units, one built on nicotinamide and one on adenine, joined by bridging phosphate groups. Molecular formula C21H27N7O14P2. It exists in oxidized (NAD+) and reduced (NADH) forms that cycle constantly during metabolism. Because oral NAD+ itself is poorly absorbed intact, most human dosing research instead uses precursor molecules — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — that the body converts into NAD+ after absorption. NAD+ and its precursors are sold as dietary supplements; NAD+ itself is also delivered as a compounded IV infusion in wellness clinics, a product category that is not FDA-approved and has been subject to at least one Class I recall for bacterial endotoxin contamination. ## How it works NAD+ is the cell's central redox carrier: it shuttles electrons through glycolysis, the TCA cycle, and oxidative phosphorylation — the core chain of reactions that turns food into usable cellular energy (ATP). Separately, NAD+ is consumed as a substrate by a set of signaling enzymes: sirtuins (SIRT1-SIRT7), which regulate genes and metabolism; PARP1, which repairs damaged DNA; and CD38, an enzyme that breaks down NAD+ and rises with age and inflammation [14]. Because CD38 activity increases with age, more of the body's limited NAD+ pool gets consumed by CD38 rather than being available for energy production or sirtuin/PARP signaling — the mechanistic argument for why supplementing with precursors might help offset age-related decline [14]. ## What the research shows *The state of the human evidence, 2025.* A narrative review of human clinical trials on NAD+ precursor supplementation in aging concluded that human trials have shown limited efficacy so far, that age-related NAD+ decline has been directly observed in only a limited number of human studies, and that tissue-specific NAD+ data remain sparse — calling for more clinical study of systemic and tissue-specific NAD+ metabolism rather than continued reliance on rodent extrapolation [11]. *NMN raises blood NAD+ and improves function markers.* A multicenter, double-blind, placebo-controlled trial gave middle-aged adults oral NMN (300-900 mg/day) for 60 days. Blood NAD+ rose in a dose-dependent way at both day 30 and day 60 versus placebo (p≤0.001), walking distance improved, and a biological-age measure did not increase; 600 mg/day was identified as the optimal dose, with no safety issues at any dose [12]. *NMN and insulin sensitivity.* A separate 10-week trial of oral NMN (250 mg/day) in prediabetic, postmenopausal women found a significant increase in muscle insulin sensitivity, measured by the gold-standard hyperinsulinemic-euglycemic clamp technique — though body composition and HbA1c did not change [13]. *NR dose-response and safety.* An 8-week trial of nicotinamide riboside (NR) at 100-1000 mg/day in healthy overweight adults raised whole-blood NAD+ by 22%, 51%, and 142% at the three doses respectively, in a clean dose-response pattern, with no flushing and no meaningful difference in adverse events versus placebo at any dose, and no disruption of cholesterol or one-carbon metabolism [15]. *The mechanistic backbone.* A foundational review across yeast, worm, mouse, and human models identifies sirtuins, PARPs, and CD38 as the major NAD-consuming enzymes competing for a shared, age-declining NAD+ pool, and frames NAD+ restoration as a candidate — not proven — strategy against age-related disease [14]. ## Reported effects, cautions & safety There is no anecdotal real-world-signals data compiled for NAD+ in this corpus, so this section skips straight to what the cited literature actually flags as a caution — most of it drawn from the acknowledged limits and controversies in the research itself, not community reports. *Cited cautions:* plain oral NAD+ capsules are poorly absorbed intact, which is why the credible human trials use precursor forms (NMN, NR) instead [11][12][15] — a supplement labeled simply "NAD+" for oral use rests on a weaker rationale than one using a validated precursor. Raising blood NAD+ is well demonstrated in trials, but translating that into hard outcomes — slower aging, disease prevention — in humans remains unproven; the 2025 review is explicit that efficacy data are still limited and tissue-specific NAD+ data are sparse [11]. Much of the strongest anti-aging data comes from rodent studies and may not extrapolate to people. IV NAD+ wellness therapy is marketed aggressively on minimal controlled human evidence; infused NAD+ clears from plasma rapidly, and infusions run too fast have been associated with chest or abdominal discomfort, flushing, and nausea. Compounded injectable NAD+ carries real contamination risk — the FDA has issued a Class I recall of a compounded NAD+ injection over elevated bacterial endotoxin. Because NAD+ supports the metabolism of proliferating cells generally, a theoretical concern exists that boosting it could also fuel existing cancer cell growth, which is why caution is advised in cancer populations. NMN's regulatory status has also been contested — the FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was first investigated as a drug, creating real marketplace uncertainty about what's actually being sold. Supplement-grade NAD+ products vary widely in purity, and third-party testing is not guaranteed. ## Where it fits in Research Peptide Fundamentals NAD+ occupies the cellular-energy and longevity corner of this desk, and it has the most human dosing data of any compound here besides tirzepatide — multiple placebo-controlled trials confirming precursors reliably raise blood NAD+. What it doesn't have yet is proof that raising blood NAD+ changes a hard clinical outcome, which puts it in an odd middle position: better-studied than [BPC-157](/bpc-157) or [KPV](/kpv) on safety and dosing, but no more proven on efficacy than either. See the [comparison page](/compare) for where all five stand on the same evidence-maturity scale. ![NAD+ research illustration — abstract cellular energy motif in cool graphite tones](/images/nad.webp) --- A no-nonsense literature rundown on research peptides — straight evidence, no sales, no dosing advice.